Title: Distinct kinetics in antibody responses to 111 Plasmodium falciparum

antigens identifies novel serological markers of recent malaria exposure

Running title: Serological signatures of malaria exposure

Authors: Yman V^{1,2*}, Tuju J³, White M T⁴, Kamuyu G³, Mwai K^{3,5}, Kibinge N³, Asghar M¹, Sundling C¹, Sondén K^{1,6}, Murungi L³, Kiboi D³, Kimathi R³, Chege T³, Chepsat E³, Kiyuka P³, Nvamako L³, Osier F H A^{3,7 #}, Färnert A^{1,6 #}

Author Affiliation:

¹ Division of Infectious Diseases, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

² Department of Infectious Diseases, Södersjukhuset, Stockholm, Sweden

³ Kenya Medical Research Institute - Wellcome Trust Research Program, Centre for Geographical Medicine Research-Coast, Kilifi, Kenva.

⁴ Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France

⁵ Epidemiology and Biostatistics Division, School of Public Health, University of the

Witwatersrand, Johannesburg, South Africa.

⁶ Department of Infectious Diseases, Karolinska, University Hospital, Stockholm, Sweden.

⁷ Centre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg, Germany.

* Corresponding author: Victor Yman, Department of Medicine Solna, Karolinska Institutet, Bioclinicum, Karolinska University Hospital, Solnavägen 30, 171 64 Stockholm. Phone: +46 (0) 709 427290, email: victor.yman@ki.se

[#]Contributed equally

Keywords: Antibody, serological signatures, traveller, longitudinal, malaria, Plasmodium falciparum, serology, IgG, exposure.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Word Count: Abstract - 147 words, Main text including methods - 5929 words

1 Abstract

2 Strengthening malaria surveillance is a key intervention needed to reduce the global disease 3 burden. Reliable serological markers of recent malaria exposure could dramatically improve 4 current surveillance methods by allowing for accurate estimates of infection incidence from 5 limited data. We studied the IgG antibody response to 111 *Plasmodium falciparum* proteins in travellers followed longitudinally after a natural malaria infection in complete absence of re-6 7 exposure. We identified a novel combination of five serological markers (GAMA, MSP1, 8 MSPDBL1 C- and N-terminal, and PfSEA1) that detect exposure within the previous 3-9 months with >80% sensitivity and specificity. Using mathematical modelling, we examined 10 the antibody kinetics and determined that responses informative of recent exposure display several distinct characteristics: rapid initial boosting and decay, less inter-individual variation 11 12 in response kinetics, and minimal persistence over time. These serological exposure markers 13 can be incorporated into routine malaria surveillance to guide efforts for malaria control and 14 elimination.

15 Introduction

16 Reducing the global burden of malaria with the aim of achieving local or regional elimination will require sustained efforts for malaria control¹. This includes the implementation and the 17 18 maintenance of high quality malaria surveillance systems that allow control programs to effectively allocate limited resources in their efforts to reduce disease transmission 2,3 . 19 20 Malaria surveillance has traditionally been based on estimates of the number of clinical cases 21 reported through health systems supplemented by data on the local prevalence of infection collected through cross-sectional surveys ⁴. However, estimates of infection incidence based 22 23 on passive case detection of clinical cases are heavily influenced by the quality of diagnosis 24 and completeness of reporting and are unreliable if asymptomatic infections are common. 25 Furthermore, the usefulness of prevalence surveys decreases substantially as transmission declines and becomes increasingly heterogeneous ^{5–7}. 26

27

Antibody responses are maintained beyond the duration of actual infections and may serve as 28 29 sensitive markers of past pathogen exposure that can complement traditional surveillance 30 data. Serology has been highlighted as a useful tool for the surveillance of a wide range of 31 infectious diseases, e.g. dengue fever, trachoma, onchocerciasis, malaria and recently COVID-19 where it is being evaluated by public health agencies worldwide $^{8-11}$. For malaria, 32 33 serological surveillance has proven particularly useful in low transmission settings and 34 antibody responses to a number of *Plasmodium falciparum* antigens, from both preerythrocytic and blood-stages, have been evaluated as exposure markers 12-15. In particular the 35 36 responses to merozoite surface protein (MSP) 1 and apical membrane antigen 1 (AMA1) have 37 been found to provide reliable population-level estimates of medium and long-term transmission trends ^{13,16–18}. The responses to these antigens on both population and individual 38 39 level, however, appear less sensitive to short-term changes in malaria transmission and

reliable serological markers of recent exposure are currently lacking ^{18,19}. A serological tool 40 41 that provides information on the magnitude of the individual-level exposure as well as the 42 time frame within which the individual was last exposed could improve surveillance by allowing for estimation of infection incidence from single time-point cross-sectional data²⁰. 43 44 Such information could be used to monitor transmission intensity and dynamics, trigger 45 intensified surveillance with focused malaria testing and treatment, guide targeted 46 interventions (e.g. using long lasting insecticidal nets or other vector control measures) and 47 subsequently evaluate their impact, or even to demonstrate the absence of transmission (reviewed in Greenhouse et al. 2018 and 2019)^{21,22}. 48

49

On the individual level, the magnitude of the malaria-specific antibody response is highly 50 affected by both the time since last infection and the level of prior exposure ^{23,24}. Although the 51 52 response is generally considered to be short-lived, accumulating data further suggest that the kinetics and the longevity of the response may vary between antigens $2^{23,25-27}$. These 53 54 observations provide a rationale for attempting to identify a combination of antigens to which the antibody responses display distinct kinetics following infection (i.e. some that are short-55 56 lived and others that are more long-lived) and allow for accurate estimation of the timing of 57 the individuals last exposure. However, an effective tool for serological surveillance would 58 have to be limited to include only a few antigens in order to be cost-effective and feasible to 59 implement at scale. Identifying the optimal combination of antigens will require a thorough 60 understanding of the kinetics of each candidate antibody response. Given the scarcity of available data on antimalarial antibody kinetics, efforts should preferably start from screening 61 a large number of candidate antigenic targets for suitability ^{26,28,29}. 62

63

64 To date, only a few studies have attempted to identify markers for individual-level exposure, 65 either by analysing cross-sectional data on antibody reactivity in longitudinally monitored individuals in endemic areas $2^{26,30-33}$ or by analysing longitudinal data on antibody responses 66 obtained from infected individuals participating in controlled human malaria infection 67 (CHMI) trials ³⁴. Helb et al. used a machine learning approach to identify candidate 68 69 serological markers of recent infection by analysing cross-sectional data on antibody 70 responses to 655 P. falciparum antigens collected at the end of a one-year follow-up of 71 children monitored actively (monthly or three-monthly) and passively for parasitaemia and 72 symptomatic infections, respectively, using microscopic examination of blood slides in an attempt to determine the timing of the last exposure prior to sampling 26 . However, in an 73 endemic setting this approach is notoriously difficult due to undetected exposure and a high 74 frequency of asymptomatic carriage of low-density sub-microscopic infections ³⁵. Although 75 76 the timing of exposure can be carefully controlled using CHMI, participants in such trials are typically treated at microscopic or PCR patency of blood-stage infection ^{36,37} and the immune 77 response observed may not reflect the response following a natural infection ³⁸. Furthermore, 78 79 CHMI studies of only primary infections ³⁴ will not capture the effect that repeated parasite exposure may have on antibody profiles and kinetics²⁴. It is possible that these uncontrolled 80 81 factors may have impacted which candidate serological markers have previously been suggested ^{26,30,31,34} 82

83

With the purpose of studying the acquisition and maintenance of both humoral and cellmediated immunity to malaria, we have established a well characterised cohort of returning
travellers (with different levels of prior malaria exposure) who are followed longitudinally in
a malaria free country after successful treatment of a naturally acquired *P. falciparum*infection ^{24,39–41}. In contrast to the design of the study by Helb et al. ²⁶, samples are collected

89 longitudinally after a known time-point of symptomatic infection. This study design offers a 90 unique opportunity to examine the kinetics of antimalarial immune responses in complete 91 absence of re-exposure. With this near-experimental set-up, we use a newly developed protein 92 microarray (KILchip v1.0⁴²) including 111 *P. falciparum* blood-stage antigens to determine 93 the antigen-specificity and kinetics of the antibody response. We identify novel serological 94 markers of recent malaria exposure and demonstrate how their ability to detect recent 95 exposure depends on the underlying kinetics of each antibody response.

96

97 **Results**

98 Sixty-five adults diagnosed with P. falciparum malaria at Karolinska University Hospital in 99 Sweden were enrolled at the time of diagnosis and followed prospectively with repeated 100 blood sampling (i.e. at enrolment, after approximately ten days, and after one, three, six, and 101 twelve months) for up to one year in complete absence of re-exposure. Out of the 65 102 participants, 21 were European natives with no prior history of malaria infection who reported 103 a limited time spent in malaria endemic areas and were considered primary infected. The 104 remaining 44 participants (39 born in Sub-Saharan Africa) reported prior malaria episodes. 105 and prolonged residency in malaria endemic areas, and were considered previously exposed. 106 The two exposure groups did not differ with regards to age, sex, time from symptom onset to 107 diagnosis, parasitaemia, or symptoms of severe malaria (Supplementary Table S1). Antibody 108 responses to 111 P. falciparum blood-stage antigens were quantified in all collected sample-109 series using the recently developed KILchip protein microarray (KILchip v1.0). Antibody 110 responses were largely positively correlated (Supplementary Fig. S1) and while many proteins 111 appeared to be highly antigenic only low-level responses were observed towards others (Fig. 112 1). As expected, the kinetics of the antibody response was antigen-specific but on average the 113 magnitude of the antibody response increased following the acute infection until

114 approximately day 10 (Fig. 2a). After day 10, there was a gradual reduction in the magnitude 115 of the response over time throughout the remainder of the follow-up period. On average, 116 individuals with prior malaria exposure displayed a greater magnitude of the response (Fig. 117 2a). A similar pattern was observed for the breadth of the response (i.e. the number of 118 antigens to which an individual is seropositive), with the peak in breadth occurring 119 approximately 10 days after the acute infection (primary infected: median = 17, range 7-71; 120 previously exposed: median = 26, range 11-77) (Fig. 2b). Although none of the participants 121 were seropositive for all antigens at any time-point, a majority of previously exposed 122 individuals acquired and maintained a substantially greater breadth of the response at the end 123 of follow-up (primary infected: median = 2, range 0-10; previously exposed: median 3, range 124 0-42) (Fig. 2b).

125

126 *Exposure-dependent differences in the magnitude and antigen-specificity of the response* 127 Linear mixed-effects regression models were used to examine differences in the magnitude of 128 the antigen-specific responses between the primary infected and the previously exposed 129 individuals. The previously exposed individuals displayed significantly greater reactivity than 130 the primary infected individuals toward 56 of the 111 antigens at the time of diagnosis, 54 at 131 day 10, 32 at 1 month, 37 at three months, and 44 antigens at both 6 and 12 months of follow-132 up (Fig. 2c). Compared to primary infected individuals, individuals with prior exposure 133 displayed a greater magnitude of the response to AMA1, erythrocyte-binding antigen (EBA) 134 175, EBA181, H101, MSP1 Block 2 (K1, MAD20, and RO33 like types) and MSP2 (full-135 length as well as FC27 and 3D7 type fragments) antigens, as well as to MSP4, MSP7, MSP9, 136 merozoite surface protein duffy binding-like (MSPDBL) 2 C-terminal, Pf113, P38, RhopH3, 137 serine repeat antigen (SERA) 3, SERA4, SERA7, and SERA9 at all time-points (Fig. 2c, 138 Supplementary Table S2). In general, the fold-difference in antibody reactivity was greater at

diagnosis and at the end of the follow-up (Fig. 2c). The observed differences, particularly at diagnosis and at the end of follow-up, indicate a more rapid induction of antibody production and better antibody maintenance upon antigenic re-stimulation suggesting the development of a memory response towards these antigens with repeated exposure. The differences in the magnitude of the response at each of the time-points are presented in full within the supplementary material (Supplementary Table S2).

145

146 Individual antibody responses most informative of recent exposure

147 What is considered a recent exposure to infection may vary depending on the epidemiological 148 setting and the purpose of a particular investigation but, in the context of *P. falciparum*, this is often defined as exposure having occurred within the past 3 to 6 months ^{22,43}. For the main 149 150 analysis, samples were treated as independent and a recent exposure was defined as the 151 infection having occurred within 3 months (i.e. 90 days) of sample collection. Consequently, 152 samples collected within 3 months of the acute infection were categorised as obtained from 153 individuals recently exposed to infection whereas the remaining samples were not. This 154 enabled the analysis of a balanced number of samples collected both before (52.5%) and after 155 (47.5%) this temporal threshold within the one-year follow-up. Because a useful serological 156 marker of recent exposure will need to accurately identify recently infected individuals 157 regardless of their prior level of exposure, data from both exposure groups were analysed 158 jointly. Receiver operating characteristics (ROC) analysis was applied to evaluate whether a 159 threshold level of the antibody response towards a single antigen could be used to accurately 160 classify if a given sample was obtained from a recently exposed individual. The analysis was 161 performed separately for each antibody response and the performance of the classifiers was 162 compared based on the classifier area under the ROC curve (AUC) (Fig. 3). Data on antibody 163 levels towards several individual antigens were able to classify samples as obtained from

164 individuals exposed within the past 3 months with comparable degrees of accuracy (Fig. 3).

- 165 The best classification performance was obtained using the antibody response towards GPI-
- anchored micronemal antigen (GAMA) for which the AUC was 0.83 (95% CI: 0.76 0.90)
- 167 reaching a sensitivity and specificity of 77%. Within this particular cohort this corresponded
- to an accuracy of 76% and a positive predictive value of 78% and a negative predictive value
- 169 of 74%. Similar results were obtained using antibody responses towards *Plasmodium*
- 170 translocon for exported proteins (PTEX) 150 (AUC= 0.82; 95% CI: 0.75 0.87),
- 171 PF3D7_1136200 (AUC = 0.81; 95% CI: 0.75 0.88), and schizont egress antigen (*Pf*SEA-1)
- 172 (AUC = 0.8; 95% CI: 0.73 0.87) for which the AUCs all exceeded 0.8 (Fig. 3,
- 173 Supplementary Table S3). In addition, the response towards MSP8, apical sushi protein
- 174 (ASP), PF3D7_0206200, MSP7-related protein (MSRP) 4, the 3D7 allelic variant of MSP3,
- and MSP1 Block 17 were among the top 10 most informative. However, for a majority of
- 176 responses the classification performance was relatively poor (Fig. 3, Supplementary Table
- 177 S3).

178 A sensitivity analysis was performed to examine whether other antibody responses would 179 have been more informative if an alternative definition of recent exposure had been used. The 180 analysis was therefore repeated using several definitions of a recent exposure (i.e. exposure 181 having occurred within 1 month, 2, 3, 4, 6, and 8 months of sample collection). Although, the 182 classifier AUCs varied depending on the definition, the same antibody responses (i.e. towards 183 GAMA, PTEX150, MSRP4, PfSEA-1, ASP, PF3D7 1136200 and MSP1 [Block 17]) were 184 consistently identified among the top 10 responses providing most accurate identification of 185 recent exposure (Supplementary Fig. S2).

187 *Combining data on multiple antibody responses to improve predictive accuracy*

188 Combining data on antibody responses towards multiple antigens could theoretically improve 189 the ability to accurately identify recently exposed individuals. Feature selection using a 190 Boruta algorithm was performed to reduce the number of potential combinations to evaluate 191 by selecting only those antibody responses contributing significant information on recent 192 exposure when analysed together for further analysis. The algorithm, which is a wrapper 193 algorithm based on a random forest classifier, was applied jointly to the full antibody data set. 194 It identified 28 antibody responses contributing significant information to classification of 195 recent exposure that were further evaluated (Fig. 4a). Similar to the results based on the 196 threshold antibody level towards a single antigen, the Boruta algorithm identified that the 197 greatest relative importance for classification was contributed by the response towards 198 GAMA, PfSEA1, PF3D7 1136200, PTEX150, and MSP8 (Fig. 4b). 199 Random forest classifiers were applied to identify a panel of up to five antibody responses 200 most informative in identifying recent exposure. The classification performance of all 201 possible two- to five-way combinations of the 28 selected responses was exhaustively 202 evaluated. There was a gradual increase in classifier performance, as indicated by an increase 203 in the cross-validated AUC, with the sequential increase in panel size from two to five 204 antibody responses. However, each increase in panel size lead to a smaller improvement in 205 classifier performance (Supplementary Fig. S3). The antibody response to GAMA was 206 included in all of the best combinations of two to four antibody responses (Supplementary 207 Fig. S3). The overall best classification performance, with a cross-validated AUC of 0.89 208 (95% CI: 0.85 - 0.94) and reaching a sensitivity and specificity of 83%, was obtained for a 209 panel of five antibody responses that included the response to GAMA, MSP1 (full length), 210 both the C- and N-terminal of MSPDBL1, and PfSEA1 (Fig. 4b). This corresponded to an 211 accuracy of 83% and positive and negative predictive values of 84% and 82%, respectively.

212	The responses to GAMA, MSP1 and the N-terminal of MSPDBL1 were included in all of the
213	top 10 most informative panels of size five, and <i>Pf</i> SEA1 was included in 8 of the top 10
214	panels. The classification performance of the top 10 antibody panels was highly comparable
215	with AUCs ranging from 0.88 (95% CI: 0.83 – 0.94) to 0.89 (95% CI: 0.85 – 0.94). The
216	random forest classifier based on a combination of five antibody responses provided a
217	significant improvement in classification accuracy compared to a simple classifier based on a
218	threshold antibody level to GAMA alone (McNemar's test: p<0.001). However, no
219	improvement was obtained using a random forest classifier fitted jointly to data on all
220	antibody responses (Cross-validated AUC: 0.83; 95% CI: 0.74 – 0.89).
221	As an additional evaluation of the robustness of the results obtained using random forest
222	classifiers, the analysis was repeated using logistic regression. The results based on logistic
223	regression classifiers were highly comparable to those obtained using random forests and are
224	presented within the supplementary material (Supplementary Fig. S4).

225

226 Identifying the antibody kinetic properties of a useful serological marker of recent

227 *exposure*

228 Certain antibody responses (e.g. to GAMA and PfSEA-1) were clearly more informative and 229 more useful as serological markers of recent exposure than others, both independently and in 230 combinations including multiple responses. A previously validated antibody kinetic model 231 was applied to quantitatively describe the kinetics of each antibody response to determine if 232 there were underlying kinetic properties shared among informative and non-informative 233 responses. The model, which captures the inter-individual variation in boosting and decay in 234 antibody levels following infection while estimating the average value and variance in the 235 kinetics across the entire cohort, was fitted separately to data for each antibody response in a 236 Bayesian framework using mixed-effects methods. The model-estimated population-level

237 parameters and corresponding variance parameters as well as the individual level parameters 238 are presented for all antibody responses within supplementary information (Supplementary 239 Tables S4 and S5). An overview of the different kinetic patterns observed is presented in Fig. 240 5 which includes data and model fits for two representative individuals as well as the model-241 estimated population-averaged kinetics of the responses towards three antigens, GAMA, 242 EBA175, and PF3D7 1252300, which were identified as highly, moderately, and minimally 243 informative of recent exposure, respectively. The major antibody kinetic patterns observed 244 were: i) a rapid increase and decay following infection with limited differences between 245 individuals with and without prior exposure (Fig 5A) ii) a rapid increase and decay following 246 infection but with substantial differences between individuals with and without prior exposure 247 (Fig 5B) iii) a limited boosting and decay following infection with or without differences 248 between individuals with and without prior exposure (Fig 5C). 249 250 To be able to present a meaningful comparison of the different kinetics (i.e. the specific 251 boosting and decay patterns) across all of the antigen-specific responses, a summary metric of 252 the individual-level antibody kinetics for each participant and antibody response was 253 generated by calculating the relative reduction (%) in antibody levels over the 1-year follow-254 up. The median relative reduction, as well as the inter-individual variation, differed 255 substantially between antibody responses (Fig. 6). The greatest relative reductions were 256 estimated for the highly antigenic proteins, e.g. GAMA and PF3D7 1136200, while the

smallest relative reductions were estimated for poorly antigenic proteins, e.g.

258 PF3D7_1343700.KELCH and MSRP5 (Fig. 6). All of the antibody responses that had

individually been identified among the top 10 most informative in identifying recent exposure

260 (i.e. GAMA, PTEX150, PF3D7_1136200, PfSEA-1, MSP8, ASP, PF3D7_0206200, MSRP4,

261 MSP33D7, Block 17 of MSP1) exhibited a substantial relative reduction in antibody levels

- 262 during follow-up (Fig. 6). For a given antibody response, there was a close association
- between the estimated relative reduction in antibody levels over time and the performance
- 264 (AUC) of the corresponding classifier of recent infection (Fig. 7). For the top 10 individually
- 265 most informative responses, there was a limited inter-individual variation in the reduction in
- antibody levels over time as well as limited differences between individuals with different
- 267 levels of prior malaria exposure and thus a consistent boosting and decay of the response
- across individuals (Fig. 6, Supplementary Fig. 5a and b).

269 **Discussion**

270 Novel and improved tools for malaria transmission surveillance are urgently needed to assist 271 effective allocation of limited resources for malaria control and assure continued progress towards malaria elimination³. There is a particular need for methods that can detect recent 272 273 exposure to infection on the individual level which can be used to generate accurate estimates of infection incidence using limited samples and data $^{20-22}$. Here, we screened plasma samples 274 275 from 65 travellers followed prospectively for up to one year after a naturally acquired P. 276 *falciparum* infection for IgG antibody responses towards 111 blood-stage antigens. Using a 277 data driven approach, we identified novel candidate serological exposure markers individually 278 informative of recent exposure and demonstrate that combining data on five responses allow 279 for accurate detection of recent exposure to *P. falciparum* within the prior 3-month period. 280 Based on a modelling approach, we then quantitatively examined the kinetics of each 281 individual antibody response and were able to characterise the kinetic properties that make a 282 particular antibody response useful as a serological marker of recent P. falciparum exposure. 283

284 When examining each of the 111 antibody responses individually, we found that the level of 285 the response to several antigens, in particular GAMA, PTEX150, PF3D7 1136200, and 286 *Pf*SEA1, were informative and could be used to identify a recent exposure with comparable 287 accuracy (Classifier AUCs all exceeding 0.8). The response to GAMA was most informative 288 and it was possible to identify a threshold antibody level such that recently exposed 289 individuals could be identified with a sensitivity and specificity of 77%. The required 290 sensitivity and specificity of a particular surveillance system, and the optimal trade-off 291 between them, should be dictated by the objective of the system, the activity the system is supposed to trigger, the availability of resources and cost of possible interventions ^{22,44,45}. The 292 293 level of accuracy in detection of recent exposure achievable using a single antibody response

could be acceptable for effective serosurveillance of population-level transmission trends
 where e.g. a lower sensitivity can be acceptable given that it remains constant over time ^{46,47}.

297 We demonstrated that the ability to accurately detect recent exposure could be significantly 298 improved if data on up to five antibody responses were analysed simultaneously using a 299 random forest algorithm. We found that the best performance was obtained based on a panel 300 of five antibody responses (AUC = 0.89), reaching a sensitivity and specificity of 83%. There 301 was no single best antibody combination, instead many panels composed of five antibody 302 responses provided comparable results. All of the top 10 panels included responses that had 303 individually been identified as highly informative (e.g. to GAMA and PfSEA-1), suggesting 304 that proteins that can identify recent infections when used individually also do well in 305 combinations. Interestingly, however, they also included responses that were individually not 306 among the more informative (i.e. to MSP1 and either one or both of the N- and C-terminal of 307 MSPDBL1) suggesting that these responses contribute additional information when used in 308 combination with individually informative responses.

309

310 The antibody responses to most of the proteins that we identified as informative of recent 311 exposure have to date not been extensively studied. Among our top 28 candidates, which were 312 informative either individually or in combination, only the responses to *Pf*SEA-1, PTEX150, 313 MSP1 (19 kDa fragment and full length), MSP2 and MSP10 have to our knowledge previously been suggested as markers of recent or concurrent infection ^{26,27,30,32,34,48}. The 314 315 response to MSP4 and SERA4 have recently been suggested as markers of recent exposure based on data from primary infections in CHMI trials ^{34,49}. However, in our study we did not 316 317 find the response to MSP4 or SERA4 informative and throughout the follow-up we observed 318 substantially greater levels of the response to these antigens in previously exposed compared

319 to primary infected individuals. We observed similar patterns for AMA1, EBA175, EBA181, 320 H101, MSP1 (Block 2) and MSP2 antigens, as well as to MSP7, MSP9, MSPDBL2 C-321 terminal, Pf113, P38, RhopH3, SERA3, SERA7, and SERA9 and believe that the prior 322 exposure-related differences in the response to all of these antigens suggest they may also (to 323 varying extents) reflect cumulative malaria exposure. This is corroborated by other studies 324 where this has been extensively demonstrated for AMA1, MSP1 (Block 17) and MSP2 ^{13,18,24,32,48,50,51}, and to some extent also reported for EBA181, MSP1 (Block 2), MSP4, MSP7, 325 MSP10, and SERA4, to which the magnitude of the response increases significantly with age 326 in populations living in areas with on-going malaria transmission ^{26,30,31,51–53}. Furthermore, the 327 328 differences in the antigen-specificity and breadth of the response in primary versus re-329 infection contribute interesting information regarding antibody acquisition and maintenance 330 that may provide insights regarding the development of malarial immunity. However, 331 investigating the immunological determinants of the observed differences was not among the 332 objectives of the present study and will therefore be explored elsewhere. 333 334 It has been suggested that what determines the usefulness of any particular response as a 335 marker of recent exposure is not just the average of its boosting or decay following infection but also the variation in these qualities across individuals 22 . When studied individually, 336 337 several antibody responses (e.g. to GAMA, PTEX150, PF3D7 1136200, PfSEA-1, and 338 MSP8) were consistently identified as the most informative in detecting recent exposure, 339 suggesting they may share common properties with regards to their kinetics. Because of the longitudinal design of the study, we were able to examine the kinetics of each antibody 340 response in detail using a previously validated mathematical model ^{23,24}. This allowed us to 341 quantitatively characterise both the antibody boosting and decay, its inter-individual variation 342 343 as well as its dependency on prior malaria exposure and to identify three key aspects that

344 make a particular antibody response a useful serological marker of recent exposure: i) a rapid 345 boosting and decay in antibody levels following clearance of infection ii) limited inter-346 individual variation in the kinetics (boosting and decay) of the response and therefore 347 predictable kinetics iii) minimal impact on the kinetics due to prior exposure and a limited 348 formation of an antibody memory response. We could also show that antibody responses that 349 were not informative of recent exposure did not exhibit this behaviour and thereby explicitly 350 demonstrate how the ability to identify recent exposure using serology is based on an 351 understanding of the underlying antibody kinetics.

352

353 In the present study we have intentionally focused solely on serology with the aim of 354 identifying a panel of antibody responses that can accurately detect recent P. falciparum 355 exposure without the use of additional data. In a surveillance context, data obtained from 356 these serological markers of recent exposure could easily be combined with parasitological 357 data as has been previously demonstrated for sero-surveillance of *P. vivax*, where Longley 358 and White et al. identified candidate serological exposure markers that can be used to detect recent exposure infection ³³, as well as for infectious disease surveillance in animal 359 populations²⁰. Furthermore, if a serological assay is to be implemented at scale for field 360 361 based surveillance it could preferably be developed into a multicomponent serological lateral 362 flow immune-chromatographic point-of-care test. In such a setup, serological detection could 363 be effectively integrated with parasite detection e.g. using ultrasensitive antigen detection 32,54,55 364

365

The unique longitudinal design of this study, in which the exact time-point of natural
exposure is known and where the absence of re-exposure during follow-up can be guaranteed,
avoids misclassification of true exposure status thereby limiting bias and providing a unique

369 opportunity to identify markers of recent exposure. Furthermore, including individuals who 370 are both primary infected and previously exposed allowed us to ascertain that our candidate 371 serological markers were able to perform equally well independently of the individuals prior 372 level of exposure. This in turn suggests that identified candidate responses could be suitable for exposure monitoring through a wide range of transmission settings ^{22,56}. We firmly believe 373 374 that further evaluation and validation of these candidate serological markers of recent 375 exposure is warranted and aim to pursue this using a range of immunoassay platforms and by 376 performing additional validation using samples collected from longitudinally followed and 377 closely monitored populations living in malaria endemic areas. 378

379 In summary, we identify novel candidate serological markers of recent exposure that, when 380 quantified individually or in combination in a single plasma sample, provide information on 381 when the donor was last exposed to P. falciparum infection. Using both a data driven and a 382 modelling approach, we demonstrate that a recent exposure is not necessarily identified by a 383 complex antibody signature that requires sophisticated algorithms for detection but rather by a 384 thorough understanding of the kinetics of the antibody response to limited number of 385 antigens. We show that the antibody responses towards highly antigenic proteins that, 386 regardless of the number of prior infections, demonstrate predictable boosting and decay 387 following a new infection are sufficient to detect whether a given individual has been exposed 388 within a defined period of time. These novel serological markers generate information that 389 can be used for malaria control purposes to understand when and where to intensify 390 surveillance, perform targeted testing and treatment, and/or deploy vector control measures, 391 and thereby effectively improve efforts to limit transmission and accelerate progress towards 392 malaria elimination.

393 Methods

Study population

395 Study participants were recruited at Karolinska University Hospital in Stockholm, Sweden.

396 Adults with *P. falciparum* malaria were enrolled at the time of diagnosis and followed

397 prospectively for up to one year with repeated blood sampling. Venous blood samples were

398 collected at the time of enrolment (i.e. at diagnosis) and follow-up samples were collected

approximately ten days, and one, three, six, and twelve months after the first sample. In total,

400 242 samples were collected from 65 participants. Data on country of birth, previous countries

401 of residence, travel history, use of antimalarial prophylaxis, previous malaria episodes and co-

402 morbidities was collected using a questionnaire administered to each study participant upon

403 enrolment as well as at the end of the follow-up period. Additional clinical data were

404 extracted from hospital records 24 .

405

406 **Ethics statement**

407 The study was approved by the Ethical Review Board in Stockholm, Sweden (Dnr 2006/893-

408 31/4 and 2013/550-32/4, 2018/2354-32, 2019-03436) and written informed consent was

409 obtained from all study participants.

410

411 Protein microarray (KILchip v1.0)

412 The KILchip v1.0 protein microarray was used for simultaneous quantification of IgG

413 antibody responses to 111 *P. falciparum* antigens ⁴². The microarray includes 82 full-length

414 proteins (or for multi-membrane proteins, the largest predicted extracellular loop) and 29

415 protein fragments from 8 unique proteins (i.e. MSP1, MSP2, MSP3, MSPDBL1, MSPDBL2,

416 *Pf*SEA-1, PF3D7_06293500 and SURFIN 4.2). A majority of proteins were produced using a

417 mammalian expression system, while a minority were produced in *Escherichia coli*. Further

details regarding the microarray method are described elsewhere ⁴². Plasma samples were 418 analysed in 1:400 dilution and bound antibody was detected using AlexaFluor⁶⁴⁷ conjugated 419 420 donkey anti-human-IgG. The processed microarray slides were read at 635 nm using a 421 GenePix® 4000B scanner (Molecular Devices) and results obtained using the GenePix® Pro 422 7 software (Molecular Devices). Positive and negative controls consisting of pooled plasma 423 from malaria exposed Kenyan adults and serum samples from malaria unexposed northern 424 European donors, respectively, were run on each slide. A 3-fold serially diluted standard 425 calibrator consisting of purified IgG from highly malaria exposed Kenyan donors was assayed 426 once within each batch.

427

428 Data analysis

429 *Data acquisition, cleaning and normalisation*

430 R (R: A language and environment for statistical computing, v3.4.4 and v3.6.1) was used for 431 data processing, normalization, and analyses. The median fluorescent intensities (MFI) of the 432 local spot background surrounding each spot was subtracted from the MFI of each antigen 433 spot. The mean MFIs of replicate spots were log-transformed to yield an approximate 434 Gaussian distribution of signal intensities. To account for technical slide-to-slide and batch-435 to-batch variation a two-step normalisation process was applied according to previously described procedures ^{57,58}. First, to account for within batch slide-to-slide effects, a Robust 436 437 Linear Model (RLM) was fitted to the log-transformed data from the positive control samples assayed on each slide. This was done separately for data from each batch ⁵⁷. After obtaining 438 439 the best-fit parameters for the slide effect the estimated coefficients for each slide was 440 subtracted from all spots within each slide. Following this within-batch RLM normalisation, a 441 second between-batch RLM normalisation was performed using data for the serially diluted 442 standard calibrator. Data for all target antigens that did not demonstrate optical saturation or

no signal was used for normalisation in both steps. A threshold of seropositivity was defined
as the mean reactivity + 3SD of the 42 negative controls. The breadth of the response within
each tested sample was defined as the number of antigens for which the reactivity exceeded
the seropositivity threshold.

447

448 *Exposure dependent differences in geometric mean antibody responses*

Linear mixed effects regression models were used to identify antigens to which responses were significantly different between primary infected and previously exposed individuals at each sampling time-point. The models were fitted separately to the log-transformed normalised MFI data for each antigen. To account for the false discovery rate (FDR) due to testing such a large number of hypotheses all p-values were FDR-adjusted according to the procedures described by Benjamini and Hochberg ⁵⁹. FDR adjusted p-values of <0.05 were considered significant.

456

457 *Identifying antibody responses informative of recent exposure to infection using binary*458 *classification based on single antibody responses*

459 For the purpose of the main analysis a recent exposure was defined as the infection having 460 occurred within 3 months (i.e. 90 days) of sample collection. All samples were categorised as 461 obtained from either a "recently infected" or "not recently infected" individual depending on 462 whether or not they were collected within this specified time frame. To evaluate if the 463 antibody response to any single *P. falciparum* antigen was informative of recent exposure, 464 binary classification using a threshold antibody level was applied to the data for each of the 465 111 antigens individually using ROC analysis. The AUC was used to compare the 466 classification performance of the individual antibody responses and confidence intervals for

the AUCs were estimated using DeLong's algorithm ⁶⁰. Alternate definitions of recent
 exposure were also evaluated as part of a sensitivity analysis.

469

470 Feature selection using a Boruta algorithm

471 Combining data on multiple antibody responses could theoretically improve the ability to accurately identify recent exposure, however, there are 2^{111} potential unique combinations of 472 antibody responses to 111 antigens and to evaluate them all was not feasible ⁶¹. To reduce the 473 number of tentative antibody response combinations to evaluate, feature selection was 474 performed using a Boruta algorithm as previously described ⁶². The Boruta algorithm is a 475 476 wrapper method built around a random forest classifier that performs a top-down search for 477 relevant features, while progressively eliminating irrelevant features, by comparing the 478 importance of original features with the importance achievable at random (estimated using 479 permuted copies of the original features). The algorithm was fitted jointly to antibody data to

480 all 111 antigens.

481

482 Identifying combinations of antibody responses informative of recent exposure to infection
483 using random forest classification

484 Following feature selection, random forest classifiers were fitted exhaustively to all possible two- to five-way combinations of the down-selected antibody responses in order to evaluate 485 whether a combination of responses could improve performance of classification of recent 486 487 infection. Classifier performance was determined by the cross-validated AUC. Cross-488 validation was performed for each classifier using repeated random sub-sampling by 489 iteratively and randomly splitting the data set into a training set (2/3) and a test set $(1/3)^{63}$. 490 For each split the model was fitted to the training set and the predictive accuracy assessed 491 using the test set. The results from 500 iterations were averaged to obtain a cross-validated

estimate of the classifier performance and the 0.025 and 0.975 quantiles of the AUC across
iterations were extracted to obtain a 95% confidence interval of the cross-validated AUC.

494

495 Modelling antibody kinetics

A previously validated mathematical model was used to estimate the antigen-specific antibody kinetics. The model captures the boosting and bi-phasic decay in antibody levels following infection and quantifies their inter-individual variation, while simultaneously accounting for differences in prior malaria exposure ^{23,24}. Briefly the model assumes that the infection causes antibody levels to rise τ_0 days before the individual presents to the hospital (where τ_0 is a parameter estimated for each individual) and that A(t) is the antibody level at time $t > \tau_0$ and is given by the following equation (1):

503

504
$$A(t) = A_{bg} + A_0 e^{-r_l(t-\tau_0)} + \beta \left((1-\rho) \frac{e^{-r_s(t-\tau_0)} - e^{-r_a(t-\tau_0)}}{r_a - r_s} + \rho \frac{e^{-r_l(t-\tau_0)} - e^{-r_a(t-\tau_0)}}{r_a - r_l} \right) (1)$$

505

506 where r_a is the rate of decay of IgG molecules; r_s and r_l are the rates of decay of short- and 507 long-lived antibody secreting cells (ASCs), respectively; β is the boost in ASCs following 508 infection at time τ_0 ; and ρ is the proportion of ASCs that are long-lived. A_0 is the preexisting levels of antibodies. For primary infected individuals, $A_0 = 0$. A_{bg} is the background 509 510 level of antibody reactivity. The models were fitted separately for each antibody response in a 511 Bayesian framework, and mixed-effects methods were used to capture the natural variation in 512 antibody kinetics between individuals while estimating the average value and variance of the 513 parameters across the entire cohort. Additionally, the antibody kinetic model accounts for 514 sample reactivity exceeding the upper limit of detection of the microarray assay. The rate of

- 515 decay in antibody reactivity was expressed as the relative reduction (%) after 1 year, starting
- from the peak of the response 64 . 516

517 Author contributions

- 518 AF, FHAO and VY planned and designed the study. VY organised the enrolment and follow-519 up of study participants and processed the samples together with KS, MA, and CS. GK, JT 520 and FHAO, designed and developed the protein microarray with assistance from LM, DK, 521 RY, EC and PK. JT, RK, and TC performed the microarray experiments. KM and NK 522 developed the data acquisition pipeline. VY and MTW performed the data analysis, and 523 MTW developed and fitted the antibody kinetic models. VY wrote the first draft of the 524 manuscript. All authors contributed to critically revising the manuscript and have approved 525 the final version.
- 526

527 Acknowledgements

528 We are grateful to all subjects for their participation in the study. We thank Ingrid Andrén,

529 Irene Nordling and fellow nurses at the Karolinska University Hospital, Department of

530 Infectious Diseases outpatient ward for assistance with coordinating follow-up visits and

sampling the study participants. We are grateful to Christine Stenström and colleagues at the

532 Karolinska University Hospital, Department of Microbiology, as well as the attending

533 physicians at the Department of Infectious Diseases, for notifying us regarding the admission

534 of patients diagnosed with *P. falciparum* malaria.

535

536 **Funding**

This work was supported by the Swedish Research Council [grant no 2015-02977 and 201802688 to AF] and by the Stockholm County Council [ALF project grant no. 20130207 and
20150135 to AF]. FHAO is supported by a Sofja Kovalevskaja Award from the Alexander
von Humboldt Foundation (3.2 - 1184811 - KEN -SKP) and an EDCTP Senior Fellowship

- 541 supported by the European Union (TMA 2015 SF1001). The funders had no role in study
- 542 design, data collection and analysis, decision to publish, or preparation of the manuscript.
- 543

544 Availability of data and materials

- 545 The datasets used and analysed during the current study are available from the corresponding
- 546 author on reasonable request.
- 547

548 Conflict of interest statement

549 We declare that there are no known conflicts of interest, financial or other.

551 **References**

- 1. Rabinovich, R. N. *et al.* malERA: An updated research agenda for malaria elimination
- 553
 and eradication. PLoS Medicine 14, e1002456 (2017).
- 554 2. The malERA Consultative Group on Monitoring Evaluation and Surveillance. A
- research agenda for malaria eradication: monitoring, evaluation, and surveillance. *PLoS*
- 556 *Med.* **8**, e1000400 (2011).
- 557 3. World Health Organization. *Global technical strategy for malaria 2016-2030. World*558 *Health Organisation.* (2015).
- 559 4. Tusting, L. S., Bousema, T., Smith, D. L. & Drakeley, C. Measuring changes in
- 560 Plasmodium falciparum transmission: precision, accuracy and costs of metrics. *Adv*.
- 561 *Parasitol.* **84**, 151–208 (2014).
- 562 5. Hay Simon, M. E. Measuring malaria endemicity from intense to interrupted
 563 transmission. *Lancet Infect. Dis.* 8, 369–78 (2008).
- 564 6. Stresman, G., Cameron, A. & Drakeley, C. Freedom from Infection: Confirming
- 565 Interruption of Malaria Transmission. *Trends in Parasitology* **33**, 345–352 (2017).
- 566 7. Cooper, L. *et al.* Pareto rules for malaria super-spreaders and super-spreading. *Nat.*567 *Commun.* 10, 1–9 (2019).
- 8. Reiner, R. C. *et al.* Time-varying, serotype-specific force of infection of dengue virus. *Proc. Natl. Acad. Sci. U. S. A.* 111, E2694-2702 (2014).
- 570 9. Bretscher, M. T. et al. Measurement of Plasmodium falciparum transmission intensity
- 571 using serological cohort data from Indonesian schoolchildren. *Malar. J.* **12**, 21 (2013).
- 572 10. Martin, D. L. *et al.* Serology for trachoma surveillance after cessation of mass drug
 573 administration. *PLoS Negl. Trop. Dis.* 9, e0003555 (2015).
- 574 11. Golden, A. et al. Analysis of age-dependent trends in Ov16 IgG4 seroprevalence to
- 575 onchocerciasis. *Parasit. Vectors* **9**, 338 (2016).

- 576 12. Kusi, K. A. *et al.* Anti-sporozoite antibodies as alternative markers for malaria
- 577 transmission intensity estimation. *Malar. J.* **13**, 103 (2014).
- 578 13. Drakeley, C. J. et al. Estimating medium- and long-term trends in malaria transmission
- 579 by using serological markers of malaria exposure. *Proc. Natl. Acad. Sci. U. S. A.* **102**,
- 580 5108–5113 (2005).
- 581 14. Cook, J. *et al.* Using serological measures to monitor changes in malaria transmission
 582 in Vanuatu. *Malar. J.* 9, 169 (2010).
- 583 15. Ondigo, B. N. et al. Estimation of Recent and Long-Term Malaria Transmission in a
- 584 Population by Antibody Testing to Multiple Plasmodium falciparum Antigens. J.
- 585 *Infect. Dis.* **210**, 1123–1132 (2014).
- 586 16. Cavanagh, D. R. et al. A longitudinal study of type-specific antibody responses to
- 587 Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in
 588 Sudan. *J. Immunol.* 161, 347–59 (1998).
- 589 17. Polley, S. D. et al. Human antibodies to recombinant protein constructs of Plasmodium
- *falciparum* Apical Membrane Antigen 1 (AMA1) and their associations with protection
- 591 from malaria. *Vaccine* **23**, 718–728 (2004).
- 592 18. Yman, V. *et al.* Antibody acquisition models: A new tool for serological surveillance
 593 of malaria transmission intensity. *Sci. Rep.* 6, 19472 (2016).
- 594 19. Wong, J. et al. Serological markers for monitoring historical changes in malaria
- transmission intensity in a highly endemic region of Western Kenya, 1994-2009.
- 596 *Malar. J.* **13**, 451 (2014).
- 597 20. Borremans, B., Hens, N., Beutels, P., Leirs, H. & Reijniers, J. Estimating Time of
- 598 Infection Using Prior Serological and Individual Information Can Greatly Improve
- 599 Incidence Estimation of Human and Wildlife Infections. *PLOS Comput. Biol.* 12,
- 600 e1004882 (2016).

- 601 21. Greenhouse, B., Smith, D. L., Rodríguez-Barraquer, I., Mueller, I. & Drakeley, C. J.
- 602Taking Sharper Pictures of Malaria with CAMERAs: Combined Antibodies to Measure
- 603 Exposure Recency Assays. Am. J. Trop. Med. Hyg. 99, 1120–1127 (2018).
- 604 22. Greenhouse, B. et al. Priority use cases for antibody-detecting assays of recent malaria
- exposure as tools to achieve and sustain malaria elimination. *Gates Open Research* **3**,
- 606 131 (2019).
- White, M. T. *et al.* Dynamics of the antibody response to *Plasmodium falciparum*infection in African children. *J. Infect. Dis.* 210, 1115–1122 (2014).
- $\frac{1}{1000} = \frac{1}{1000} = \frac{1$
- 609 24. Yman, V. et al. Antibody responses to merozoite antigens after natural Plasmodium
- falciparum infection: Kinetics and longevity in absence of re-exposure. *BMC Med.* 17,
 (2019).
- 612 25. Kinyanjui, S. M., Conway, D. J., Lanar, D. E. & Marsh, K. IgG antibody responses to
 613 Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life.

614 Malar. J. 6, (2007).

- 615 26. Helb, D. A. et al. Novel serologic biomarkers provide accurate estimates of recent
- 616 *Plasmodium falciparum* exposure for individuals and communities. *Proc. Natl. Acad.*

617 *Sci.* **112**, E4438–E4447 (2015).

- 618 27. Perraut, R. *et al.* Serological signatures of declining exposure following intensification
 619 of integrated malaria control in two rural Senegalese communities. *PLoS One* 12,
 620 e0179146 (2017).
- 621 28. King, C. L. *et al.* Biosignatures of Exposure/Transmission and Immunity. *Am. J. Trop.*622 *Med. Hyg.* 93, 16–27 (2015).
- Proietti, C. *et al.* Immune Signature Against Plasmodium falciparum Antigens Predicts
 Clinical Immunity in Distinct Malaria Endemic Communities. *Mol. Cell. Proteomics* **19**, 101–113 (2020).

- 626 30. Helb, D. Anti-malarial Antibody Responses & Applications for Assessing Malaria
 627 Exposure. (UC Berkeley, 2015).
- Kobayashi, T. *et al.* Distinct Antibody Signatures Associated with Different Malaria
 Transmission Intensities in Zambia and Zimbabwe. *mSphere* 4, (2019).
- 630 32. van den Hoogen, L. L. *et al.* Selection of Antibody Responses Associated With
- 631 Plasmodium falciparum Infections in the Context of Malaria Elimination. *Front.*

632 *Immunol.* **11**, 928 (2020).

- 633 33. Longley, R. J. et al. Development and validation of serological markers for detecting
- 634 recent Plasmodium vivax infection. *Nat. Med. 2020 265* **26**, 741–749 (2020).
- 635 34. van den Hoogen, L. L. et al. Antibody Responses to Antigenic Targets of Recent
- 636 Exposure Are Associated With Low-Density Parasitemia in Controlled Human

637 Plasmodium falciparum Infections. *Front. Microbiol.* 9, 3300 (2018).

- 638 35. Wu, L. et al. Comparison of diagnostics for the detection of asymptomatic Plasmodium
- *falciparum* infections to inform control and elimination strategies. *Nature* 528, S86–
 S93 (2015).
- 641 36. Sheehy, S. H. *et al.* ChAd63-MVA-vectored blood-stage malaria vaccines targeting
- 642 MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
- 643 *Mol. Ther.* **20**, 2355–68 (2012).
- 644 37. Walker, K. M. *et al.* Antibody and T-cell responses associated with experimental
- human malaria infection or vaccination show limited relationships. *Immunology* **145**,

646 71–81 (2015).

- 647 38. Scholzen, A. & Sauerwein, R. W. Immune activation and induction of memory: lessons
 648 learned from controlled human malaria infection with Plasmodium falciparum.
- 649 *Parasitology* **143**, 224–35 (2016).
- 650 39. Homann, M. V. et al. Detection of Malaria Parasites After Treatment in Travelers: A

651	12-months Longitudina	l Study and Statistical	Modelling Analysis.	EBioMedicine 25,
-----	-----------------------	-------------------------	---------------------	------------------

652 66–72 (2017).

- 40. Asghar, M. *et al.* Cellular aging dynamics after acute malaria infection: A 12-month
 longitudinal study. *Aging Cell* 17, e12702 (2018).
- 41. Sundling, C. et al. B cell profiling in malaria reveals expansion and remodeling of
- 656 CD11c+ B cell subsets. JCI Insight 4, (2019).
- 42. Kamuyu, G. *et al.* KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein
- 658 Microarray to Facilitate Malaria Vaccine Candidate Prioritization. *Front. Immunol.* 9,
- 6592866 (2018).
- 660 43. World Health Organization. *Disease surveillance for malaria elimination : an*
- 661 *operational manual.* (World Health Organization, 2012).
- 662 44. Drewe, J. A., Hoinville, L. J., Cook, A. J. C., Floyd, T. & Stärk, K. D. C. Evaluation of
 663 animal and public health surveillance systems: a systematic review. *Epidemiol. Infect.*664 140, 575–590 (2012).
- 665 45. Groseclose, S. L. & Buckeridge, D. L. Public Health Surveillance Systems: Recent

Advances in Their Use and Evaluation. *Annu. Rev. Public Health* **38**, 57–79 (2017).

- 667 46. Guidelines Working Group. Updated Guidelines for Evaluating Public Health
 668 Surveillance Systems. (2001).
- 669 47. Avdicova, M. et al. Data quality monitoring and surveillance system evaluation: A
- handbook of methods and applications. *ECDC Technical Document* 1–91 (2014).
- 671 doi:10.2900/35329
- McCallum, F. J. *et al.* Differing rates of antibody acquisition to merozoite antigens in
 malaria: implications for immunity and surveillance. *J. Leukoc. Biol.* 101, 913–925
 (2016).
- 675 49. Burel, J. G. et al. Dichotomous miR expression and immune responses following

- 676 primary blood-stage malaria. JCI insight 2, (2017).
- 677 50. Stewart, L. et al. Rapid assessment of malaria transmission using age-specific sero-

678 conversion rates. *PLoS One* **4**, e6083 (2009).

- 679 51. Weber, G. E. et al. Sero-catalytic and Antibody Acquisition Models to Estimate
- 680 Differing Malaria Transmission Intensities in Western Kenya. Sci. Rep. 7, 16821
- 681 (2017).
- 682 52. Perraut, R. *et al.* Association of antibodies to Plasmodium falciparum merozoite
 683 surface protein-4 with protection against clinical malaria. *Vaccine* 35, 6720–6726
- 684 (2017).

Adu, B. *et al.* Antibody levels against GLURP R2, MSP1 block 2 hybrid and AS202.11
and the risk of malaria in children living in hyperendemic (Burkina Faso) and hypoendemic (Ghana) areas. *Malar. J.* 15, (2016).

- 688 54. Landier, J. *et al.* Operational performance of a plasmodium falciparum ultrasensitive
- 689 rapid diagnostic test for detection of asymptomatic infections in eastern Myanmar. J.
- 690 *Clin. Microbiol.* **56**, (2018).
- 691 55. Mwesigwa, J. *et al.* Field performance of the malaria highly sensitive rapid diagnostic
 692 test in a setting of varying malaria transmission. *Malar. J.* 18, 288 (2019).
- 693 56. Longley, R. J. et al. Naturally acquired antibody responses to more than 300
- 694 Plasmodium vivax proteins in three geographic regions. *PLoS Negl. Trop. Dis.* 11,
 695 e0005888 (2017).
- 57. Sboner, A. *et al.* Robust-Linear-Model Normalization To Reduce Technical Variability
 in Functional Protein Microarrays research articles. *J. Proteome Res.* 8, 5451–5464
 (2009).
- 58. Sill, M., Schröder, C., Hoheisel, J. D., Benner, A. & Zucknick, M. Assessment and
 optimisation of normalisation methods for dual-colour antibody microarrays. *BMC*

701 *Bioinformatics* **11**, 556 (2010).

- 59. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
- 703 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series*
- 704 *B* (*Methodological*) **57**, 289–300 (1995).
- 705 60. Sun, X. & Xu, W. Fast implementation of DeLong's algorithm for comparing the areas
- vinder correlated receiver operating characteristic curves. *IEEE Signal Process. Lett.*

21, 1389–1393 (2014).

- 708 61. Nilsson, R., Peña, J. M., Björkegren, J. & Tegnér, J. Consistent Feature Selection for
- 709 Pattern Recognition in Polynomial Time. J. Mach. Learn. Res. 8, 589–612 (2007).
- 710 62. Kursa, M. B., Rudnicki, W. R., Hastie, T., Tibshirani, R. & Friedman, J. Feature
- selection with the Boruta Package. J. Stat. Softw. **36**, (2010).
- Dubitzky, Werner; Granzow, Martin; Berrar, D. *Fundamentals of data mining in genomics and proteomics*. (Springer Science & Business Media., 2007).
- 714 64. White, M. et al. Antibody kinetics following vaccination with MenAfriVac: an analysis
- of serological data from randomised trials. *Lancet Infect. Dis.* **19**, 327–336 (2019).

717 Figures

Fig. 1. A heat map of the normalized median fluorescent intensity (MFI) of the antibody response to each of the 111 antigens included on the KILChip V1.0 Microarray. Rows correspond to individual antigens while columns correspond to individual samples. Antigens are sorted from top to bottom by decreasing average normalised MFI across all samples. Samples are sorted first by exposure status, second by sampling time-point and third by average normalised MFI across all antigens.

724

Fig. 2. Differences in average antibody reactivity related to prior exposure

726 a) Box-plot of the overall magnitude of the antibody response to *P. falciparum* over time 727 (averaging signal intensities over all antigens for each individual) in individuals with (grey) or 728 without (magenta) prior malaria exposure. b) Box-plot of the breadth of the response over 729 time in individuals with (grey) or without (magenta) prior malaria exposure. The breadth is 730 expressed as the total number of antigens (out of the 111) to which the individual responds. c) 731 Volcano plot of the fold-difference in geometric mean antibody reactivity between individuals 732 with or without prior malaria exposure vs. the FDR-adjusted P-value at each of the sampling 733 time-points. Linear mixed-effects regression models fitted to the Log-transformed antibody 734 data were used to estimate the mean fold-difference of the response for each antigen between 735 primary infected and previously exposed participants. P-values were FDR-adjusted for 736 multiple comparisons using the procedure described by Benjamini and Hochberg. A log₂ (fold 737 difference) of greater than 0 indicates antigens to which the geometric mean response is 738 greater among previously exposed individuals and conversely a log₂ (fold-difference) of less 739 than 0 indicates antigens to which the geometric mean response is greater among primary 740 infected individuals. Antibody responses that differ significantly between exposure groups are 741 highlighted in red and the 20 antigens for which the difference is greatest are named in the

figure. Further details of this comparison are included within the supplementary information(Supplementary Table S2).

744

Fig. 3. Receiver operating characteristic (ROC) curve for classifying individuals as
infected within 90 days using a threshold antibody level to a single antigen. Coloured
curves correspond to the top 10 antibody responses that were most accurate in detecting
recent infection as determined by the classifier area under the ROC curve (AUC).

749

750 Fig. 4. Feature selection of antibody responses and evaluation of most informative 751 antibody combinations. a) Variable importance plot for classification performance 752 determined using a Boruta feature selection algorithm as described by Kursa and Rudnicki. 753 The Boruta algorithm was fitted jointly to data for all antibody responses. Antibody responses 754 are ordered from left to right by their importance for classification. The importance measure 755 is defined as the Z-score of the mean decrease accuracy (normalized permutation importance). 756 Blue boxes correspond to the minimal, average, and maximum Z-scores of shadow features. 757 Red boxes indicate variables not contributing significantly to accurate classification. Green 758 boxes indicate the 28 antibody responses contributing significantly to classification that were 759 selected for further evaluation. b) Cross-validated receiver operating characteristic (ROC) 760 curves. Random forest classifiers fitted to data on antibody responses to the top 10 761 combinations of 5 out of the 98280 possible combinations of the 28 selected antigens as 762 determined by the classifier area under the ROC curve (AUC). An AUC of 0.5 indicates a 763 classifier that performs no better than random, while an AUC of 1 indicates a perfect 764 classifier. Lines correspond the ten classifiers with the highest cross-validated AUCs. 765

766 Fig. 5. Individual- and population-level antibody kinetics for the responses to three 767 representative antigens (GAMA, EBA175, and PF3D7 1252300) in primary infected and 768 previously exposed individuals. The major antibody kinetic patterns observed were: a) a 769 rapid increase and decay following infection with limited differences between individuals 770 with and without prior exposure, b) a rapid increase and decay following infection but with 771 substantial differences between individuals with and without prior exposure, and c) a limited 772 boosting and decay following infection with or without differences between individuals with 773 or without prior exposure. The top row displays the antibody kinetics for two representative 774 study subjects who were either primary infected (ID: 2015006) or previously exposed (ID: 775 2013008). The dots denote the individual sample antibody reactivity. The solid lines denote 776 the model predicted antibody boost and decay patterns relative to the collection of the first 777 sample at time t = 0 and the shaded area the 95% credible interval of the prediction. The 778 bottom row displays the geometric mean antibody reactivity over time in each exposure group 779 relative to the collection of the first sample at time t = 0. The grey and magenta dots denote 780 the average reactivity in previously exposed and primary infected individuals, respectively, at 781 each sampling time point. The red dots denote average reactivity in negative control samples. 782 The solid lines denote the model predicted mean boosting and decay in each exposure group 783 and the shaded area the 95% confidence interval.

784

785 Fig. 6. Box-plot of individual antigen-specific relative reduction (%) in antibody levels 786 after one year of follow-up. Responses are ordered from left to right by smallest to largest 787 relative reduction in antibody levels. The individual responses identified as top 10 most 788 informative in detecting recent infection based on a threshold antibody level to a single 789 antigen are highlighted in red.

791 Fig. 7. Relationship between classification accuracy and the relative reduction in

antibody levels. Mean relative reduction in antibody levels after 1 year of follow-up versus

- classifier performance as evaluated using the classifier area under the receiver operating
- characteristic (ROC) curve (AUC). Colours indicate the antibody responses identified as top
- 10 most accurate in detecting recent infection, when using the response to a single antigen.
- 796 Vertical and horizontal error bars represent the 95% confidence interval (CI) of the estimated

mean relative reduction in antibody levels and classifier AUCs, respectively.

798

799 Supplementary Information

File S1: Supplementary Information. Supplementary Table S1 and Supplementary Figs. S1-

801 S5.

802

803 File S2: Supplementary Table S2. Results from linear mixed effects models examining the

804 difference in antibody levels between primary infected and previously exposed individuals.

805 All antigens and time-points for which antibody levels were significantly different between

the two exposure groups are presented within the table.

807


File S3: Supplementary Table S3. Results from ROC analysis of identifying recent exposure
(within 3 months) based on a threshold antibody level for all individual antigens.


810


File S4: Supplementary Table S4. The antibody kinetic model estimated population-level
parameters and corresponding variance parameters.

813

File S5: Supplementary Table S5. The antibody kinetic model estimated individual-level
parameters.









Importance

b a ROC curve for classifying recent P. falciparum infections: Boruta Variable Importance Random Forest (5 Antigens) 100% 20 80% 15 -True positive rate (sensitivity) 60% 10· 40% 5 GAMA, MSP1, MSPDBLC.terminal, MSPDBLN.terminal, PFSEA; AUC = 0.888 (95% CI: 0.845 – 0.942) GAMA, MSP1, MSPDBLN.terminal, PF10_0166, PFSEA; AUC = 0.887 (95% CI: 0.81 – 0.942) 0 20% GAMA, MSP1, MSPDBLN.terminal, PF3D7_0730800.2, PFSEA, AUC = 0.884 (95% CI: 0.834 - 0.94) GAMA, MSP1, MSPDBLN.terminal, PFSEA, Surfin4.2K1; AUC = 0.883 (95% CI: 0.822 - 0.946) GAMA, MSP1, MSPDBLN.terminal, PF10_0166, Surfin4.2K1A; AUC = 0.882 (95% CI: 0.833 - 0.938) GAMA, MSP1, MSPDBLC.terminal, MSPDBLN.terminal, Surfin4.2K1; AUC = 0.882 (95% CI: 0.832 - 0.944) GAMA, MSP1, MSPDBL2N.terminal, MSPDBLN.terminal, PFSEA; AUC = 0.882 (95% CI: 0.83 – 0.937) GAMA, MSP1, MSPDBLN.terminal, MSRP4, PFSEA; AUC = 0.881 (95% CI: 0.825 + 0.945) GAMA, MSP1, MSPDBLN.terminal, PFSEA, Surfin4.2K1A; AUC = 0.88 (95% CI: 0.824 - 0.941) -5 GAMA, MSP1, MSP2CHO, MSPDBLN.terminal, PFSEA; AUC = 0.88 (95% CI: 0.83 - 0.943) %0 0% 20% 40% 60% 80% 100% False positive rate (100 - specificity)

а









<25%

>75%

50-75%

